Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 1
3(50.0%)
6Total
Phase 2(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06125951Phase 2Active Not Recruiting

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Role: lead

NCT02727699Phase 2Completed

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Role: lead

NCT04983368Phase 1Completed

A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers

Role: lead

NCT02616445Phase 1Completed

Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects

Role: lead

NCT03830762Phase 1Completed

Xanamem™ in Healthy Elderly Subjects

Role: lead

NCT05657691Phase 2Completed

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Role: lead

All 6 trials loaded